Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin

Roberto P. Santos, Pablo J. Sánchez, Asuncion Mejias, Daniel K. Benjamin, Thomas J. Walsh, Sanjay Patel, Hasan S. Jafri

Research output: Contribution to journalArticle

42 Scopus citations


Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalPediatric Infectious Disease Journal
Issue number4
Publication statusPublished - Apr 2007



  • Liposomal amphotericin B
  • Micafungin
  • Pharmacokinetic
  • Preterm infant
  • Primary cutaneous aspergillosis
  • Voriconazole

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this